News & Topics

2015.09.24 Joint Announcement with Ajinomoto Co., Inc.Notification of the Beginning of Sales of StemFIT® AK02N High-Performance Culture Solution for Regenerative Medicine Use Human iPS Cells

Joint Announcement with Ajinomoto Co., Inc.Notification of the Beginning of Sales of StemFIT® AK02N High-Performance Culture Solution for Regenerative Medicine Use Human iPS Cells

2015.09.08 Announcement: ReproCELL concludes license agreement with Keio University for the exclusive sale of myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells

ReproCELL concludes license agreement with Keio University for the exclusive sale of myocardial cells derived from disease-type (long QT syndrome, a congenital heart disease) iPS cells

2015.08.26 Joint Press Announcement with Institute for Frontier Medical Sciences, Kyoto University: New high-performance cryopreservation solution for human ES/iPS cells used in regenerative medicine, Notice of the commencement of sales of “ReproCryo DMSO free”

Joint Press Announcement with Institute for Frontier Medical Sciences, Kyoto University: New high-performance cryopreservation solution for human ES/iPS cells used in regenerative medicine, Notice of the commencement of sales of “ReproCryo DMSO free”

2015.08.14 Announcement: “Advancing Towards Regenerative Medicine” and “Regarding the Issuance of No. 10 Warrants”

Supplemental Information regarding the Issuance of No. 10 Warrants(1):Advancing Towards Regenerative Medicine Supplemental Information regarding the Issuance of No. 10 Warrants(2):Explanation of “Commit Issue”

2015.08.04 Announcement: Reprocell’s project, “Prototype Development of a Large-Scale Production Mechanism of Highly Functional Cardiomyocytes Derived From Human iPS Cells”, has been chosen to receive a Subsidy for Collaborative Projects to Advance the Creation of an Innovative Manufacturing Industry (FY 2015-2016). The subsidy will be added to the income statement as non-operating income.

Announcement: Reprocell’s project, “Prototype Development of a Large-Scale Production Mechanism of Highly Functional Cardiomyocytes Derived From Human iPS Cells”, has been chosen to receive a Subsidy for Collaborative Projects to Advance the Creation of an Innovative Manufacturing Industry (FY 2015-2016). The subsidy will be added to the income statement as non-operating income.”

2015.07.29 Announcement: Diseased neurons derived from iPS cells of Alzheimer’s disease patients Initiation of sales of “ReproNeuro AD-patient”

Diseased neurons derived from iPS cells of Alzheimer’s disease patients Initiation of sales of “ReproNeuro AD-patient”

2015.07.22 Announcement: Sales commencement of “ReproNeuro MQ Medium”, a cell culture kit which enables the creation of high-functioning nerve cells derived from human iPS cells

Announcement: sales commencement of “ReproNeuro MQ Medium”, a cell culture kit which enables the creation of high-functioning nerve cells derived from human iPS cells”

2015.06.30 Stemgent, a ReproCELL Group Company Launches a New High Performance Self-replicative RNA Reprogramming Kit

Stemgent, a ReproCELL Group Company Launches a New High Performance Self-replicative RNA Reprogramming Kit

2015.06.24 ReproCELL Concludes the License Agreement with Keio University for the Exclusive Sale of Disease (Hypertrophic Cardiomyopathy) Type Myocardial Cells Derived from iPS Cells

ReproCELL Concludes the License Agreement with Keio University for the Exclusive Sale of Disease (Hypertrophic Cardiomyopathy) Type Myocardial Cells Derived from iPS Cells

2015.06.22 ReproCELL Launches New Culture Medium for High Quality Human Naïve iPS Cells, “ReproNaïve™”

ReproCELL Launches New Culture Medium for High Quality Human Naïve iPS Cells, “ReproNaïve™”